2-methyl-1-N-(methylideneamino)-4-N-[2-[3-(3-propyloxiran-2-yl)oxyphenyl]quinazolin-4-yl]benzene-1,4-diamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-methyl-1-N-(methylideneamino)-4-N-[2-[3-(3-propyloxiran-2-yl)oxyphenyl]quinazolin-4-yl]benzene-1,4-diamine
• 化学式: C₂₇H₂₇N₅O₂
• 分子量: 453.5
• InChiKey: IIOBOQWLEJEKNQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8
• 重原子数：
  34
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  84
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Pharmacokinetically improved compounds
  申请人：SURFACE LOGIX, LLC

  公开号：US10570123B2

  公开（公告）日：2020-02-25

  The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease.

  本发明涉及 ROCK1 和 ROCK2 的抑制剂以及调节此类化合物药代动力学和/或药效学特性的方法。本发明还提供了可用于治疗疾病的抑制 ROCK1 和/或 ROCK2 的方法。
• PHARMACOKINETICALLY IMPROVED COMPOUNDS
  申请人：SURFACE LOGIX, INC.

  公开号：US20180072710A1

  公开（公告）日：2018-03-15

  The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease.